On this page
LONP1
lon peptidase 1, mitochondrial
LONP1 is located on the short (p) arm of chromosome 19, at band 19p13.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 19 in the library →Available at Jeen Health
Clinical tests that include this
Overview
LONP1 (lon peptidase 1, mitochondrial) is located on chromosome 19 at position p13.2 and encodes a 959-amino-acid protein that functions as a major quality-control protease within mitochondria. The enzyme recognises and degrades misfolded, damaged, or oxidised proteins in the mitochondrial matrix, preventing the accumulation of dysfunctional protein aggregates that could impair cellular respiration. This housekeeping role is particularly important in tissues with high energy demands, such as the brain, muscle, and lens of the eye. When LONP1 function is compromised, mitochondrial protein homeostasis deteriorates, which can manifest in a variety of clinical presentations ranging from neurological impairment to metabolic disturbance.
What the gene does
The LONP1 protein operates as an ATP-dependent serine protease within the mitochondrial matrix, where it selectively identifies and cleaves damaged or misfolded polypeptides. By removing proteins that have been oxidatively damaged or incorrectly assembled, LONP1 helps maintain the functional integrity of the mitochondrial proteome. The enzyme also participates in regulating levels of certain mitochondrial proteins under stress conditions, contributing to the cellular response to oxidative stress and energy deficit. LONP1 exhibits chaperone-like activity as well, assisting in the proper folding of newly imported mitochondrial proteins before they are incorporated into respiratory complexes or metabolic pathways. This dual protease-chaperone function positions LONP1 as a central guardian of mitochondrial protein quality, ensuring that the organelle can sustain efficient ATP production and metabolic homeostasis across diverse physiological demands.
Video: Genetics 101
Chromosome location
LONP1 is located on the short arm of chromosome 19 at cytogenetic band 19p13.2. The gene spans a genomic region that encodes the full-length 959-amino-acid mitochondrial protease. Chromosome 19 is gene-dense and contains numerous loci implicated in metabolic and neurological processes, consistent with LONP1's role in mitochondrial function.
Protein structure
The LONP1 protein comprises 959 amino acids and features a modular architecture adapted for its dual protease and chaperone roles. The Lon N-terminal domain (amino acids 124-370) is thought to mediate substrate recognition and oligomerisation, enabling the enzyme to assemble into active hexameric or heptameric complexes. Two disordered regions (amino acids 77-102 and 218-257) likely provide structural flexibility that facilitates conformational changes during substrate binding and ATP hydrolysis. The Lon proteolytic domain (amino acids 759-949) harbours the active-site serine residue responsible for peptide-bond cleavage, allowing LONP1 to degrade misfolded or damaged polypeptides within the mitochondrial matrix. This domain organisation reflects the enzyme's need to coordinate ATP binding, substrate recognition, and catalytic activity in a regulated manner.
Key variants
Pathogenic variants in LONP1 typically reduce or abolish the protease activity of the encoded enzyme, leading to accumulation of damaged mitochondrial proteins. Both missense changes affecting critical functional residues and loss-of-function variants have been reported. The variant spectrum reflects the gene's intolerance to functional disruption, as even partial loss of LONP1 activity can compromise mitochondrial protein homeostasis and energy metabolism.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1391G>A | p.Trp464Ter | Pathogenic | ★☆☆☆ | Inborn genetic diseases |
c.1412dup | p.Lys472fs | Pathogenic | ★☆☆☆ | Fetal anomalies with a likely genetic cause |
c.2154+1G>C | - | Pathogenic | ★☆☆☆ | LONP1-related disorder |
c.2175C>A | p.Tyr725Ter | Pathogenic | ★☆☆☆ | not provided |
c.56_77dup | p.Gly28fs | Pathogenic | ★☆☆☆ | not provided |
c.798_804del | p.Pro267fs | Pathogenic | ★☆☆☆ | not provided |
c.1892C>A | p.Ser631Tyr | Pathogenic | - | CODAS syndrome |
c.2171C>T | p.Ala724Val | Pathogenic | - | CODAS syndrome |
c.2353A>G | p.Arg785Gly | Pathogenic | - | CODAS syndrome |
c.901C>G | p.Arg301Gly | Pathogenic | - | not provided |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Individuals with biallelic pathogenic variants in LONP1 may present with a range of mitochondrial phenotypes, often involving the central nervous system, eyes, and skeletal system. Clinical features can include intellectual disability, developmental delay, bilateral congenital cataracts, and skeletal dysplasia. Some affected individuals exhibit biochemical findings consistent with inborn errors of metabolism, such as elevated lactate or pyruvate, reflecting impaired mitochondrial respiratory-chain function. The phenotypic variability likely relates to the residual activity of the variant LONP1 protein and the specific tissues most vulnerable to mitochondrial protein-quality-control failure.
No disease links recorded for this gene in our reference set.
UK clinical status
LONP1 appears on multiple green-rated gene panels within the NHS Genomic Medicine Service, reflecting its recognised role in mitochondrial and developmental disorders. These include the Mitochondrial disorders panel, the Intellectual disability panel (R29), the Bilateral congenital or childhood onset cataracts panel (R31), the Skeletal dysplasia panel (R104), and the Likely inborn error of metabolism panel (R98). Green classification indicates that there is strong evidence linking LONP1 variants to the clinical presentations covered by these panels. The gene is also listed on the DDG2P resource, the Fetal anomalies panel (R21), the Possible mitochondrial disorder - nuclear genes panel (R63), the Pyruvate dehydrogenase deficiency panel (R316), and the Undiagnosed metabolic disorders panel, underscoring its relevance to a broad spectrum of rare genetic conditions assessed through UK clinical genomics pathways.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What does the LONP1 gene do?
LONP1 encodes a protease enzyme in mitochondria that degrades damaged or misfolded proteins, maintaining protein quality and supporting efficient energy production. It also assists in the proper folding of newly imported mitochondrial proteins.
How are LONP1 variants inherited?
LONP1-related conditions typically follow an autosomal recessive pattern, meaning an affected individual inherits a pathogenic variant from each parent. Carriers with one variant generally do not show symptoms.
Which NHS panels include LONP1?
LONP1 is listed on multiple green-rated NHS panels, including Mitochondrial disorders, Intellectual disability, Bilateral congenital or childhood onset cataracts, Skeletal dysplasia, and Likely inborn error of metabolism, among others.